JointHealth™ express October 31, 2013
New addition to Manitoba’s formulary
Certolizumab Pegol (Cimzia®) for the treatment of rheumatoid arthritis has newly been listed for coverage on Manitoba’s drug formulary.
As of October 17th, certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Manitoba’s drug formulary. Click here to view the detailed medication criteria.
Now there are more treatment options available in Manitoba, which is important because every patient responds differently to disease suppressing or modifying medications.
Certolizumab pegol is an anti-TNF medication taken by subcutaneous injection every two weeks. Request for coverage must be made by a physician who is a specialist in rheumatology.
To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manage your disease.
Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.
New addition to Manitoba’s formulary
Certolizumab Pegol (Cimzia®) for the treatment of rheumatoid arthritis has newly been listed for coverage on Manitoba’s drug formulary.
As of October 17th, certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Manitoba’s drug formulary. Click here to view the detailed medication criteria.
Now there are more treatment options available in Manitoba, which is important because every patient responds differently to disease suppressing or modifying medications.
Certolizumab pegol is an anti-TNF medication taken by subcutaneous injection every two weeks. Request for coverage must be made by a physician who is a specialist in rheumatology.
To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manage your disease.
Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.